MWNA
ABCL icon

Marshall Wace North America’s AbCellera Biologics ABCL Stock Holding History

Marshall Wace North America’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-77,638
Closed -$2.64M – 1399
2021
Q1 		$2.64M Buy
+77,638
New +$3.09M 0.01% 738

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Marshall Wace North America's ABCL Position: Q2 2021 in Review

Marshall Wace North America sold out of AbCellera Biologics (ABCL) in Q2 2021, closing a stake of 77,638 shares — an estimated $2.64M sold.

Marshall Wace North America first reported a position in ABCL in Q1 2021 and held it in 1 quarter. The position peaked at $2.64M in Q1 2021. 114 funds tracked by Wall St. Rank hold ABCL as of Q2 2021.

  • Marshall Wace North America reported no remaining AbCellera Biologics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 77,638 AbCellera Biologics shares in Q2 2021, an estimated $2.64M.
  • Marshall Wace North America first reported a position in AbCellera Biologics in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's AbCellera Biologics position peaked at $2.64M in Q1 2021.
  • 114 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.